Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease and a portfolio company of Qiming Venture Partners, announces its commercial presence in the Asia Pacific (APAC) region with the installation of the ARGO? HT System, an advanced ultra-sensitive proteomics platform, at the prestigious Hong Kong Center for Neurodegenerative Diseases (HKCeND). 

The ARGO? HT System along with the NULISA? Platform are designed to revolutionize biomarker discovery by enabling researchers to detect and quantify proteins at unprecedented levels of sensitivity and accuracy. 

The partnership with HKCeND will focus on unlocking new insights into the molecular mechanisms of neurodegenerative diseases such as Alzheimer's disease, and Parkinson's disease. The ARGO? HT System and NULISA? Platform deployments will empower HKCeND's researchers to identify novel biomarkers, accelerate drug development, and improve early detection and personalized treatment strategies for patients.

"Expansion of the ARGO? HT installed base to the APAC region represents a significant step forward in our vision to bring transformative proteomics solutions to researchers worldwide," said Dr. Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences. "We are excited to contribute to HKCeND's vibrant scientific community and support groundbreaking advancements in the fight against neurodegenerative diseases."

 Prof. Nancy Ip, the Director of Hong Kong Center for Neurodegenerative Diseases (HKCeND), added, "The integration of the NULISA? Technology enabled by the ARGO? HT System into our research infrastructure is a game-changer. This technology will allow us to explore the proteomic underpinnings of neurodegenerative diseases in ways that were previously unimaginable."